Table 5 Summary of profile treatment sequences before and after pazopanib (SAS)
Pazopanib N = 190 n (%) | |
|---|---|
Patients receiving treatments before pazopanib | 14 (7.3) |
Interferon | 12 (6.3) |
Nivolumab and ipilimumab | 1 (0.5) |
Epacadostat | 1 (0.5) |
Pembrolizumab | 1 (0.5) |
Patients receiving treatments after discontinuing pazopanib | 52 (27.4) |
Nivolumab | 21 (40.4) |
Axitinib | 13 (25.0) |
Everolimus | 13 (25.0) |
Sunitinib | 9 (17.3) |
Cabozantinib | 5 (9.6) |
Lenvatinib | 3 (5.8) |
Sorafenib | 2 (3.8) |
Reasons for switching to pazopanib | 15 (7.9) |
Disease progression | 11 (73.3) |
Lack of tolerability | 2 (13.3) |
Other | 1 (6.7) |
Physician decision | 1 (6.7) |
Reasons for switching from pazopanib | 52 (27.4) |
Disease progression | 45 (86.5) |
Adverse event | 7 (13.5) |